A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

NCT05245084 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension and Dyslipidemia

Interventions

DRUG: CKD-386(3)
DRUG: D013, D326, D337

Sponsor

Chong Kun Dang Pharmaceutical